STAGE IIIB LUNG CANCER AJCC V8

This study tests whether giving chemotherapy and immunotherapy both before and after surgery is better than only after surgery for people with stage II-IIIB non-small cell lung cancer that can be removed. About 1,100 adults will be randomly assigned to one of the two approaches. …

This study looks at whether adding chemotherapy to immunotherapy (pembrolizumab) helps older adults (70+) with advanced non-small cell lung cancer live longer compared to immunotherapy alone. About 304 participants will receive either the combination or just immunotherapy. The go…

This study compares two treatments for people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). One group gets the targeted drug osimertinib alone, the other gets osimertinib plus bevacizumab, which blocks blood vessel growth to tumors. The…

This study tests whether adding local treatments (like surgery or radiation) to the immunotherapy drug durvalumab can help control stage III lung cancer that has started to grow again after standard treatment. About 51 adults whose cancer has progressed after chemoradiation and d…

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…

This study tests whether giving two immunotherapy drugs (cemiplimab and fianlimab) before surgery can kill more cancer cells in people with early-stage non-small cell lung cancer. About 60 adults with stage IB to IIIB lung cancer will receive the drug combination, then have their…

This study tests whether doing special breathing exercises before lung cancer surgery can lower the chance of problems like pneumonia or breathing trouble after the operation. About 220 people with stage I-IIIB lung cancer will either do the training or receive usual care. The go…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy after surgery helps people with stage II to IIIB non-small cell lung cancer live longer without the cancer returning. About 1,210 participants will receive either the combination or sequ…

This study tests whether giving the immunotherapy drug durvalumab after surgery can prevent early-stage non-small cell lung cancer from returning. About 306 people who have had their lung cancer completely removed will either receive durvalumab or be watched closely (the usual ap…

This study tests whether the drug canakinumab can prevent lung cancer in people who have suspicious lung nodules that haven't gone away. About 50 participants will receive the drug to see if their nodules shrink or disappear, and to track how many develop lung cancer over time. T…

This study tests a smarter way to give radiation to people with lung cancer. Normally, the radiation plan is made before treatment starts, but tumors can shrink during treatment, which may expose healthy tissue to unnecessary radiation. In this study, the radiation plan is update…

This study tests whether a special yoga program can improve physical function, fatigue, sleep, and quality of life for people with lung or esophageal cancer who are getting radiation therapy, and also for their family caregivers. About 400 patient-caregiver pairs will take part. …

This study looks at how biomarkers (like DNA in the blood) can help predict whether immunotherapy will work for people with advanced non-small cell lung cancer. Researchers will collect blood and tissue samples from about 535 participants to understand treatment response and find…

This study looks at how chemoradiation for locally advanced lung cancer affects the heart. Researchers will track heart injury and fitness in 100 patients, using each person's risk profile to tailor treatment and potentially reduce heart damage. The goal is to learn how to better…

This study looks at how the bacteria in your gut might influence stomach issues like diarrhea and colitis caused by certain cancer drugs (immune checkpoint inhibitors). Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung cancer, or genito…